There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xenon (XENE – Research Report), Caribou Biosciences (CRBU – Research Report) and Arcus Biosciences (RCUS – Research Report) with bullish sentiments.
Xenon (XENE)
Leerink Partners analyst Marc Goodman reiterated a Buy rating on Xenon on November 8 and set a price target of $46.00. The company’s shares closed last Thursday at $30.00.
According to TipRanks.com, Goodman is a 2-star analyst with an average return of
Currently, the analyst consensus on Xenon is a Strong Buy with an average price target of $52.14, implying a 56.0% upside from current levels. In a report issued on November 8, TD Cowen also maintained a Buy rating on the stock.
See the top stocks recommended by analysts >>
Caribou Biosciences (CRBU)
In a report issued on November 7, Mani Foroohar from Leerink Partners reiterated a Buy rating on Caribou Biosciences, with a price target of $25.00. The company’s shares closed last Thursday at $3.95, close to its 52-week low of $3.44.
According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Caribou Biosciences is a Strong Buy with an average price target of $22.00, representing a 376.2% upside. In a report issued on October 31, Evercore ISI also initiated coverage with a Buy rating on the stock with a $13.00 price target.
Arcus Biosciences (RCUS)
In a report issued on November 8, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcus Biosciences. The company’s shares closed last Thursday at $13.74.
According to TipRanks.com, Graybosch is ranked 0 out of 5 stars with an average return of
Arcus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $47.60, representing a 195.7% upside. In a report issued on November 6, Truist Financial also maintained a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XENE:
- Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
- Xenon Pharmaceuticals reports Q3 EPS (73c), consensus (77c)
- Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Is XENE a Buy, Before Earnings?
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
